[Biotecnologia Cina-Hong Kong]Tengsheng Biopharma (2137.HK) announces positive clinical data at IDWeek 2022 to support continued development of new HIV treatment candidates
Tengsheng Boyao Biotechnology Co., Ltd. (hereinafter referred to as “Tengsheng Boyao” or the “Company”, stock code: 2137.HK), a multinational enterprise dedicated to developing innovative treatments for unmet patient needs and major diseases of public health, today announced updated data from two Phase 1 studies in healthy US volunteers evaluating long-acting BRII-732 and BRII-778, two candidate investigational drugs designed to treat infection with human immunodeficiency virus (HIV). The results of both studies show that once weekly administration of BRII-732 and BRII-778 is safe and well tolerated, a potential first-class oral HIV combination therapy in development is provided an important data carrier. The results of both studies were presented in a poster session at IDWeek 2022.
One of the posters, titled “Safety, Tolerability, and Pharmacokinetic Features of Islatravir’s Medoxomil Carbonate Prodrug BRII-732 in Healthy Adult Subjects”, highlights the use of oral BRII-732 in a single increasing dose (SAD) up to 200 mg and multiples increasing doses (MAD) up to 25 mg, demonstrated acceptable safety and tolerability and an excellent linear pharmacokinetic profile (PK) to achieve therapeutic goals. These data reinforce the therapeutic potential of BRII-732 as a combined antiretroviral regimen that includes once weekly dosing.
“Our HIV research program aims to improve the standard of care for the more than 38 million people living with HIV worldwide, many of whom wish to improve the management of this lifelong infection by enabling access to new treatment options that are more convenient to administer. These results suggest that BRII-732 and BRII-778 hold promise as a safe and well-tolerated new patient treatment option that could help alleviate patients’ daily drug burden and even improve the social stigma that many people currently living with HIV face.forward to advance the clinical development of two compounds, BRII-732 and BRII-778, into the next phase of research in an effort to provide patients with the first combination therapy long-acting oral “.
Another poster presented at IDWeek titled “Safety, Tolerability, and Pharmacokinetic Profile of the oral modified-release formulation of Rilpivirine BRII-778 in healthy adult subjects” demonstrated single-dose ascending (SAD) and multiple-dose ascending (MAD) administration of BRII ) of -778 formulations are generally safe and well tolerated, with a linear pharmacokinetic (PK) profile consistent with slower oral absorption. week provides key information.
Additionally, 16 abstracts published at IDWeek 2022 by Tengsheng Biopharmaceutical’s 3 strategic development partners presented infectious disease projects jointly developed with Tengsheng Biopharmaceuticals. This collective presentation on IDWeek further strengthens Tengsheng Biopharma’s scientific advances in developing a combination of anti-infectious drugs to address a range of infectious diseases that place significant public health burdens on people around the world. Among them, Tengsheng Biopharma has jointly promoted candidates for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative bacterial infections with Qpex Biopharma in Greater China and jointly promoted candidates for the treatment of non-tuberculous mycobacteria with rights of AN2 therapeutic license for drugs.
David Margolis, Ph.D., Head of Infectious Diseases Therapeutics at Tengsheng Biopharmaceuticals, said, “This solid clinical data set from the Tengsheng Biopharmaceuticals HIV program and our collaborative projects in the field of multidrug-resistant (MDR) and widely drug-resistant Antibiotics resistant (XDR) not only highlights The company’s experience and leadership in infectious diseases is a testament to our ongoing commitment to developing unique treatment options for patients and providers in areas of great medical need and rapidly developing medical needs. growth. scientific breakthroughs and patient needs and working to develop innovative therapeutic candidates for some of the most common diseases in the world, including HIV. Current oral HIV treatment options are limited to lifelong daily dosing and many HIV-infected people find this method of administration problematic e has seriously affected daily life ”.
